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Abstract
Background: Metastatic breast cancer remains incurable. Next-generation sequencing (NGS) offers the ability to
identify actionable genomic alterations in tumours which may then be matched with targeted therapies, but the
implementation and utility of this approach is not well defined for patients with metastatic breast cancer.
Methods: We recruited patients with advanced breast cancer of any subtype for prospective targeted NGS of their
most recent tumour samples, using a panel of 108 breast cancer-specific genes. Genes were classified as actionable
or non-actionable using the European Society of Medical Oncology Scale for Clinical Actionability of Molecular
Targets (ESCAT) guidelines.
Results: Between February 2014 and May 2019, 322 patients were enrolled onto the study, with 72% (n = 234) of
patients successfully sequenced (n = 357 samples). The majority (74%, n = 171) of sequenced patients were found to
carry a potentially actionable alteration, the most common being a PIK3CA mutation. Forty-three percent (n = 74) of
patients with actionable alterations were referred for a clinical trial or referred for confirmatory germline testing or
had a change in therapy outside of clinical trials. We found alterations in AKT1, BRCA2, CHEK2, ESR1, FGFR1, KMT2C,
NCOR1, PIK3CA and TSC2 to be significantly enriched in our metastatic population compared with primary breast
cancers. Concordance between primary and metastatic samples for key driver genes (TP53, ERBB2 amplification) was
> 75%. Additionally, we found that patients with a higher number of mutations had a significantly worse overall
survival.
Conclusion: Genomic profiling of patients with metastatic breast cancer can have clinical implications and should
be considered in all suitable patients.
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Background
Breast cancer remains the most common malignancy
and cause of cancer-associated death amongst women
worldwide [1, 2]. For patients with metastatic breast can-
cer (MBC) the disease is almost always fatal, with 5-year
survival rates of approximately 26% [3, 4]. In early-stage
breast cancer, treatment decisions are guided by the
clinical subtypes of oestrogen receptor positive (ER+
HER2−), human epidermal growth factor receptor 2
amplified (HER2+) and triple-negative breast cancer
(TNBC), which are defined by the presence or absence
of the oestrogen receptor and progesterone receptor and
HER2 overexpression or gene amplification. This broad
classification does not account for significant tumour
evolution during disease progression, driven by selective
pressures [1, 5]. Additionally, germline mutation testing
for breast cancer patients, which could identify target-
able alterations across all patients, is only common in
the cases of young women, male breast cancer, or indi-
viduals with a strong family history [6].
There are an increasing number of agents that target
specific genomic alterations, especially mutated protein
kinases [7, 8]. Identification of suitable patients and
gaining access to the corresponding targeted therapy has
been challenging due to the cost of sequencing technol-
ogy, the requirement in the past for non-formalin-fixed
material, the inherent intra-tumoural heterogeneity of
breast cancer and the lack of frequently occurring gen-
omic alterations that can be targeted. In MBC, few genes
are mutated at a frequency above 10%, leaving a wide
array of infrequently altered potential targets [8]. Due to
the rarity of these targets, clinical trials of targeted ther-
apies are challenging to conduct.
In the era of precision oncology, few large-scale genomic
studies have focused on metastatic breast cancer, and hence,
our understanding of the breast cancer genome has relied on
large-scale studies in primary tumours [7, 9, 10]. However, it
is now well established that early breast cancer and MBC
may have differing genomic profiles even in the same patient.
More data surrounding the genomic landscape of MBC will
be useful to identify oncogenic drivers specific for advanced
disease with potential therapeutic implications, such as ESR1
and resistance to endocrine therapies [10, 11].
Here we describe such an initiative, from an academic
tertiary referral cancer centre, where individuals with
MBC had their tumour samples prospectively profiled
using a targeted next generation sequencing (NGS)
assay. The aim of this study was to explore the feasibility
and clinical relevance of this approach.
Methods
Patient recruitment and samples
From January 2014 to May 2019, 322 patients were re-
cruited from across Australia. All patients signed informed
consent at Peter MacCallum Cancer Centre outpatient
clinics (ethics committee approved study 13/123). Key in-
clusion criteria included age 18 years or over, histological
confirmation of breast cancer and a life expectancy greater
than 3months. Patients of any gender, and with any breast
cancer subtype or sites of disease, were allowed on study.
Following successful enrolment, baseline information in-
cluding relevant medical history, Eastern Cooperative On-
cology Group performance status, past treatment and
intended treatment were collected. Updates to the clinical
history including survival follow-up were evaluated every
3months.
Tumour tissue was requested for all recruited patients
from various anatomical pathology service providers.
Wherever possible, both primary and metastatic samples
were obtained. Tissues were received as formalin-fixed,
paraffin-embedded (FFPE) unstained sections at 5-μM
thickness with up to 20 sections requested per sample.
Prior to DNA extraction, a single slide was stained with
haematoxylin and eosin to confirm the presence of can-
cer and to evaluate for tumour cellularity and tumour-
infiltrating lymphocytes (TIL) in the sample [12].
Next-generation sequencing genomic profiling
Tumour DNA was extracted after micro- or macro-
dissection (sample dependent) on sections stained with
methyl green and quantified using the Fluorometric
Qubit High Sensitivity system (ThermoFisher Scientific,
USA). A minimum of 100 ng of DNA was required to
proceed to sequencing.
A custom gene panel targeting all exons of genes re-
currently altered in breast cancer was designed for the
Agilent SureSelectXT Target Enrichment System (Agi-
lent Technologies, Santa Clara, CA, USA) using the Sur-
eDesign tool (Table 1). This platform utilises
biotinylated RNA baits for hybrid capture of desired
DNA. Prior to library preparation with the KAPA Hyper
Prep Kit (KAPA Biosystems, USA), DNA for each sam-
ple was randomly fragmented using ultrasonication
(Covaris Inc., USA). Libraries passing quality control
underwent hybrid capture with the custom RNA baits
using the Bravo automated liquid handling robot (Agi-
lent Technologies, Australia). Captured libraries were
indexed and pooled prior to paired end sequencing on
the Illumina MiSeq or NextSeq. A process matched
non-tumour control sample was included in each run
for use in downstream analysis. A total of 20 runs have
been performed over the study, with a range of 10–40
samples per run.
Assessment of gene actionability
Table 1 is adapted from the European Society for Med-
ical Oncology (ESMO) and their European Society of
Medical Oncology Scale for Clinical Actionability of
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Table 1 Targeted sequencing panel and actionable genes as per ESMO guidelines
Gene Alteration type
LEVEL 1: “known actionable alteration”
AKT1 E17K, other pathogenic mutations
BRCA1/ BRCA2 Germline mutations
ESR1 Somatic mutations, previously reported
ERBB2 Amplification and mutation
PIK3CA Somatic mutations
PTEN Homozygous deletions, loss of function mutations
LEVEL 2: “potentially actionable alteration”
ARID1A Somatic mutations
ATM Somatic mutations
BRCA1/BRCA2 Somatic mutations
CDH1 Somatic mutations
ERBB3 Somatic mutations
HRAS Somatic mutations
IGF1R Somatic mutations
INPP4B Somatic mutations
MAP2K4 Somatic mutations
MAP3K1 Somatic mutations
MDM2 Amplifications
PIK3R1 Somatic mutations
RB1 Somatic mutations
Non-actionable genes
AKT2 FANCC NRAS
AKT3 FANCG PALB2
ALK FBXW7 PDGFRA
APC FGFR1 PIK3R3
AXIN2 FGFR2 PMS2
BAP1 FGFR3 PRKAR1A
BLM FGFR4 PTCH1
BMPR1A FH PTPN11
BRAF FLCN RAD51C
BRIP1 FOXA1 RAD51D
BUB1B GATA3 RECQL4
CASP8 KIT RET
CBFB KRAS RUNX1
CCND1 MAP2K1 SDHA
CCND2 MAX SDHB
CDC73 MCL1 SDHC
CDK4 MEN1 SDHD
CDKN2A MET SF3B1
CHEK2 MLH1 SMO
CTNNB1 KMT2D STK11
DDB2 KMT2C TBX3
EGFR MSH2 TMEM127
Geelen et al. Breast Cancer Research           (2020) 22:91 Page 3 of 13
Molecular Targets (ESCAT) guidelines [13]. These clas-
sify the actionability of genes according to various levels
of evidence (LOE). As indicated in Table 1, level 1 ac-
tionable corresponds to ESCAT LOE I/II, whilst level 2
actionable genes is equivalent to LOE III/IV. Although
amplification of ERBB2 is considered to be a level 1 ac-
tionable alteration, because it is the defining factor of
the HER2+ breast cancer subtype, it is not included in
the analysis. All patients classified as HER2+ would
therefore have a level 1 actionable alteration; it is ex-
cluded from the analysis because it defines the HER2+
breast cancer subtype and is part of standard diagnostic
testing.
Tumour-infiltrating lymphocyte (TIL) quantity evaluation
TIL analysis was performed wherever possible on avail-
able H&E slides as per the International TILs Working
Group guidelines by a single pathologist (RS) [14].
Bioinformatics analysis
Raw sequencing data had adapters trimmed with cuta-
dapt (v1.6–1.9.1) [15]. The Burrows-Wheeler Aligner al-
gorithm was used to align sequencing reads to the
human genome (GRCh37), with no altered parameters
[16]. The Depth of Coverage tool in the Genome Ana-
lysis Tool Kit (GATK 3) was used to calculate the mean
coverage accounting for overlapping read pair ends [17].
Duplicate reads were removed with Picard Tools (v1.77–
v1.141) [18]. VarDict (v1.3.0–1.5.7) was used to call vari-
ants that were then annotated with ANNOVAR [19, 20].
CopywriteR (v2.0.1–2.0.6) was used to call copy number
(CN) alterations from off-target reads with a bin width
of 50 kb [21]. A mean log ratio > 0.7 was considered
amplified, and < 0.7 indicative of a heterozygous or
homozygous deletion.
Manual curation was then used to identify the variants
most likely pathogenic and relevant to the patient’s dis-
ease. This included removing samples with a read depth
of less than 100, a variant allele frequency less than 5%
and variants with strand bias. Additionally, only variants
that led to a protein change (non-synonymous), those lo-
cated in the exonic region of the gene and those not
found in either the 1000 genomes population or the
ESP650 cohorts were included in the analysis [22, 23].
Integrative Genomics Viewer was then utilised to con-
firm the presence of the mutation and exclude sequen-
cing error or variants in highly repetitive regions (either
homopolymers > 4 bases in length or triplet nucleotide
repeats) [24]. Any mutation in TP53, BRCA1, or BRCA2
that had a variant allele frequency greater than 20% was
referred for consideration of germline testing.
A report was generated on the sequencing results of each
patient, including an estimation of the likelihood of the mu-
tation’s oncogenic relevance and potential therapeutic op-
tions including clinical trials. This estimation of oncogenic
relevance was calculated using various resources including
the ClinVar, the Catalogue of Somatic Mutations in Cancer,
OncoKB and medical literature [25–27].
Statistical analysis
Survival analysis was performed using Cox regression
models. In all cases, overall survival was calculated from date
of study consent to either date of death or date of last
follow-up. Time of diagnosis for both primary and metastatic
disease was calculated from the first biopsy confirmation of
cancer, or if a biopsy was unsuitable, first imaging to confirm
the presence of cancer. Somatic interaction analysis and cal-
culation was performed using the pair-wise Fisher’s exact test
to detect co-occurring gene pairs and the CoMet ExactTest
algorithm [28–30]. Concordance scores were calculated by
dividing the number of concordant observations by the total
number of observations per genetic alteration. The same
principle was applied to calculate individual patient concord-
ance scores. Calculations for mutation numbers were per-
formed using one sample from every patient, ideally a
metastatic sample; however, when no metastatic sample was
available, a primary sample was included instead. Adjustment
for multiple testing was performed using the method of Ben-
jamini and Hochberg. All statistical analysis was performed
using R software (R version 3.6.2 (2019-12-12)).
Results
Between February 2014 and May 2019, 322 patients with
MBC were recruited. The majority of these patients were
Table 1 Targeted sequencing panel and actionable genes as per ESMO guidelines (Continued)
Gene Alteration type
ERBB4 MSH6 TP53
ERCC2 MUTYH TSC1
ERCC3 NBN TSC2
ERCC4 NCOR1 VHL
ERCC5 NF2 WT1
EXT1 NOTCH1 XPA
FANCA NOTCH2 XPC
Level 1 actionable alterations are equivalent to ESMO ESCAT LOE I and II, whilst level 2 actionable alterations are equivalent to LOE III and IV as described in [13]
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ER+HER2− (68%, n = 219), with HER2+ and TNBC
representing 12% (n = 38) and 20% (n = 65) respectively.
The median age of these patients was 46 years (23–74)
at primary diagnosis and 52 years (24–78) at metastatic
diagnosis (Table 2).
Across the cohort, 748 tumour samples were re-
quested, with an average of 2 samples per patient
(Fig. 1a). In total, 82% (n = 614) of the requested samples
were received; however, the time between request and
receipt varied considerably with an average of 29 days
for samples stored by the parent institution and 49 days
for samples retrieved from external pathology providers.
Amongst the received samples, 35% (n = 215) had in-
sufficient DNA quantity for sequencing, and the
remaining 65% (n = 399) underwent sequencing with a
success rate of 90% (n = 357). The failure rate of 10% of
samples (n = 42) was largely attributed to poor quality
DNA due to FFPE fixation, as neither the age of the
sample nor its location were significant predictors of
failure. The majority of the failed sequencing samples
came from primary lesions (70%, n = 29). Metastatic
samples, from sites such as lymph node (12%, n = 5),
liver (5%, n = 2) and lung (5%, n = 2), accounted for less
than a quarter of sequencing failures. A single specimen
Table 2 Study cohort clinical features
Overall (n =
322)
ER+HER2− (n = 219,
68%)
HER2+ (n = 38,
12%)
TNBC (n = 65,
20%)
P value
Median age at primary diagnosis (range) 46 (23–74) 46 (24–73) 43.5 (34–74) 47 (23–74)
Median age at metastatic diagnosis
(range)
51 (24–78) 52 (30–78) 45.5 (35–67) 50 (24–76)
Median age at consent (range) 52 (24–81) 54 (30–78) 48 (36–81) 52 (24–77)
Median DFI1 (range) 40 (1–312) 54.5 (1–312) 25 (4–136) 23 (1–252)
De novo patients 71 (22%) 50 (22%) 14 (36%) 7 (11%)
Treatment history
Previous chemotherapy
Yes 309 (96%) 208 (95%) 37 (97%) 64 (98%)
No 8 (2%) 7 (3%) 1 (3%) 0
Unknown 5 (2%) 4 (2%) 0 1 (2%)
Previous Endocrine therapy Chi squared: <
0.0001
Yes 222 (69%) 205 (94%) 11 (29%) 6 (9%)
No 95 (29%) 10 (5%) 27 (71%) 58 (89%)
Unknown 5 (2%) 4 (1%) 0 1 (2%)
Lines of treatment in metastatic
setting
Chi squared: 0.003
1 28 (9%) 12 (5%) 1 (3%) 16 (25%)
2 70 (22%) 47 (21%) 4 (11%) 19 (29%)
3 72 (22%) 45 (21%) 13 (34%) 14 (22%)
> 3 133 (41%) 103 (47%) 20 (53%) 10 (15%)
Unknown 20 (6%) 12 (5%) 0 6 (9%)
Sequenced patients
Sequenced 234 (72%) 162 (75%) 25 (66%) 47 (72%)
Not sequenced due to sample failure 18 (6%) 12 (6%) 1 (3%) 5 (8%)
Not sequenced due to other2 70 (22%) 45 (19%) 12 (31%) 13 (20%)
Patients with actionable mutations3 171 (74%) 131 (80%) 11 (44%) 29 (61%) Chi squared: 0.0001
Level 1: 114 (49%) 93 (57%) 6 (24%) 15 (32%)
Level 2 57 (25%) 38 (24%) 5 (20%) 14 (30%)
No actionable alterations 63 (26%) 31 (19%) 14 (56%) 18 (38%)
DFI disease-free interval (time in months)
1Patients with de novo metastatic disease not included. 2Other reasons for not being sequenced aside from sequencing failure include: sample not received or
insufficient DNA quantity for sequencing. 3Percentage calculated from number of sequenced patients. Numbers shown are reflective of the overall total and then
the total within each subtype. The HER2+ subtype does not include patients with ERBB2 amplification (100%, n = 25)
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from the bone, ovary, brain and skin also failed sequen-
cing (2% each). Ultimately, this led to 72% (n = 234) of
recruited patients being successfully sequenced. The ma-
jority of samples sequenced successfully were primary
tumours (53%, n = 189). Samples from metastatic lymph
nodes (10%, n = 37) and the liver (9%, n = 31) accounted
for the majority of metastatic samples (n = 168, 47%).
Other metastatic sites included bone (7%, n = 26), brain
Fig. 1 Study cohort. a Recruitment and specimen retrieval flow chart. Sample information and numbers are shown on the left of the central
chart and patient information and numbers are shown on the right. b Actionable alterations. Pie chart shows the percentage breakdown of
patients and the level of actionable alterations their samples contain. Patients with at least one level 1 actionable alteration amounted to 49%
(n = 114). Patients with a level 2 actionable alteration accounted for 25% (n = 57). Patients without an actionable alteration amounted to 26% of
the cohort (n = 60). c Level 1 actionable alteration breakdown by number of samples. AKT1 mutations (3%, n = 4), BRCA1/2 germline variants (7%,
n = 9), ESR1 mutations (12%, n = 16), ERBB2 mutations (10%, n = 14), PIK3CA mutations (52%, n = 71) and PTEN mutations (17%, n = 23). ERBB2
amplifications are not included. d Level 2 actionable alteration breakdown by number of samples. ARID1A mutations (12%, n = 21), ATM mutations
(1%, n = 2), BRCA1/2 non-germline mutations (12%, n = 21), CDH1 mutations (27%, n = 48), ERBB3 mutations (5%, n = 9), HRAS mutations (1%, n = 1),
IGF1R mutations (3%, n = 6), INPP4B mutations (5%, n = 9), MAP2K4 mutations (4%, n = 7), MAP3K1 mutations (9%, n = 16), MDM2 amplifications
(7%, n = 12), PIK3R1 mutations (6%, n = 11) and RB1 mutations (8%, n = 14)
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(5%, n = 19), lung (3%, n = 12) and ovarian (2%, n = 6).
The remaining 6 metastatic samples each came from a
unique site and accounted for overall 2% (n = 6). Paired
primary and metastatic tissue was available for 35% of
patients (n = 81).
Across the sequenced samples, there was a median of 3
non-synonymous somatic mutations per sample (range 0–
10) and 4 focal CN alterations (range 1–28). Level 1 alter-
ations were found in 49% (n = 114) of all patients
sequenced and 25% (n = 57) of all patients were found to
carry a level 2 change (Fig. 1b). This amounts to 74% (n =
171) of patients harbouring a potentially actionable alter-
ation. The majority of these samples were of the ER+
HER2− subtype (77%, n = 131), with HER2+ and TNBC
subtypes accounting for 6% (n = 11) and 17% (n = 29) of
the total cohort respectively. Fifty-seven percent of ER+
HER2− cases (n = 93/162), 24% of HER2+ (n = 6/25) and
32% of TNBC cases (n = 15/47) had level 1 alterations.
As shown in Fig. 1c, PIK3CA was the most common
level 1 actionable alteration, being found in 30% of se-
quenced patients and accounting for 52% of patients
with level 1 actionable mutations (n = 71). Of the cohort
with actionable alterations (n = 171), 43% (n = 74) were
referred onto a molecularly targeted clinical trial. The
majority of these patients had PIK3CA mutations (89%,
n = 68), followed by 2 patients with PTEN mutations,
and 4 patients with ERBB2 mutations. A further 2 pa-
tients with FGFR1 amplifications were referred for FGFR
inhibitor trials, although this gene is not considered ac-
tionable according to ESMO Clinical Actionability
guidelines [13]. Of ER+HER2− patients, 10% (n = 24)
were found to carry an ESR1 mutation in their meta-
static tumour sample. Nearly all of these patients had
been treated with prior endocrine therapy (Table 2).
A total of 21 patients were found to harbour BRCA1 or
BRCA2 mutations. Of these, 36% (n=8) were previously known
pathogenic germline BRCA1 or BRCA2 carriers. The remaining
64% (n=13) were referred on to germline testing. Of these pa-
tients, 2 were confirmed to carry germline variants of unknown
significance, 5 confirmed wild type and 6 patients did not attend
germline testing. A previously known pathogenic germline muta-
tion in CHEK2 was also identified in a single patient.
Figure 2a shows the genomic landscape of the se-
quenced metastatic samples (n = 167 samples). Amongst
these samples, TP53 was the most commonly altered at
40%, followed by PIK3CA, CCND1, NCOR1 and FGFR1.
In order to identify any gene that may be enriched in
the metastatic cohort, the mutational frequencies were
compared to those in the TCGA breast cancer dataset
comprised of primary tumours [31]. The genes AKT1,
BRCA2, CHEK2, ESR1, FGFR4, KMT2C, NCOR1,
PIK3CA and TSC2 were significantly enriched in our
metastatic study population compared to the TCGA co-
hort (Supplementary Table 1).
We performed an analysis to identify alterations that
may be significantly co-occurring or mutually exclusive.
Each subtype was analysed individually using the 25 most
frequently altered genes within each cohort. In ER+HER2
− metastatic samples (n = 112) (Fig. 2b and Supplementary
Table 2), 43 gene-pairs were found to significantly co-
occur. When this analysis was performed in the TNBC
subtype (n = 40 samples), only 2 gene pairs were found to
be co-occurring: RB1 and FGFR1 (p = 0.01), as well as
CHEK2 and CDH1 (p = 0.025). In the ER+HER2− group,
RB1 mutations were found to co-occur with 8 other genes,
suggesting a significant role within this subtype (Supple-
mentary Table 2). Overall, in our cohort TNBC metastatic
samples have less significantly co-occurring genes than
ER+HER2− breast cancers.
The concordance of key driver alterations was investi-
gated between primary and metastatic samples (Fig. 3)
across the 81 patients (35%) of the cohort with paired
samples. Of note, PIK3CA was largely concordant with a
score of 69% (n = 20/29 patients). In the 9 patients who
displayed discordance, the PIK3CA mutation was found
exclusively in the metastatic lesion in 5 patients and ex-
clusively in the primary lesion in 4 patients. The only
gene to show 100% concordance was BRAF (n = 4 pa-
tients); however, TP53, FGFR1 amplification, ERBB2
amplification and IFG1R showed concordance scores
greater than 75%. FOXA1, STK11, TSC1 and TSC2 were
found to have no concordance between tumours and
were largely restricted to metastases (Fig. 3). When
tumour concordance was evaluated within each patient,
only 18% (n = 15 patients) were found to have 100% con-
cordance between their primary and metastatic lesion,
whilst 7% of patients (n = 6) had no concordant findings,
highlighting the genomic heterogeneity of metastatic
breast cancer within individual patients.
We investigated factors associated with survival, and un-
surprisingly, the clinical subtype (Fig. 4a) had a significant
impact on overall survival (OS). When the time between
primary disease and metastatic disease diagnosis was com-
pared amongst the patients, those with a longer disease-
free interval had a significantly better OS (hazard ratio
(HR) = 0.61, confidence interval (CI) = 0.39–0.94, p =
0.02). Amongst the patients with sequenced samples, we
found that higher mutation number was associated with
significantly worse survival (HR = 1.1 per mutation, CI =
1.0–1.2, p = 0.01, Fig. 4b). This trend was observed in both
the ER+HER2− subtype (HR 1.1, CI = 1.0–1.2, p = 0.04;
Fig. 4c) and the HER2+ subtype (HR = 2.5, CI = 1.1–5.3,
p = 0.02), but not in the TNBC subtype (HR = 1.1, CI =
0.86–1.4, p = 0.4; Fig. 4d). The same subtype level analysis
was performed using copy number; however, no signifi-
cant results were observed.
Although breast cancer is not commonly considered
to be immunogenic, the presence of TILs has been
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known to impact survival in primary breast cancer [32].
In our dataset, TILs in the metastatic lesion were
not significantly associated with OS for any subtype,
as calculated from time of metastatic diagnosis (Sup-
plementary Table 3). As anticipated, amongst the
primary samples, TNBC patients with a higher num-
ber of TILs had a significantly longer DFI
(Supplementary Table 3). This was also evident using
the TNBC metastatic samples, where those with
higher TILs had a significantly longer disease-free
interval than those with lower TILs (HR 4.07, CI
1.2–13.6, p value: 0.02). Consistent with previous
data some metastatic sites had significantly greater
TIL infiltrate (Fig. 4e) [33].
Fig. 2 Metastatic mutational landscape. a Oncoplot of somatic mutations identified at a frequency of 10% or more in sequenced metastatic
samples (n = 168). Percentage frequency of the genes is shown in the barchart to the left of the central plot. Clinical subtype and mutation type
are indicated on their respective legend. For genes significantly enriched in this cohort compared to TCGA, see Supplementary Table 1. b
Mutational co-occurrence plot for metastatic ER+HER2− samples (n = 112). Degree of significance indicated in the legend, with only results of the
top 25 genes shown. No mutational exclusivity pairs were identified. For individual p values, see Supplementary Table 2
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Discussion
In this study, 49% (n = 114) of patients were found to
harbour a level 1 actionable alteration, which corre-
sponds to the ESCAT LOE I/II genes. Level 1 actionable
alterations were of high clinical relevance with 65% (n =
74/111) of patients with alterations in this category re-
ferred for clinical trial. Level 2 actionable alterations
were identified in 25% (n = 57) of patients and did not
impact clinical decision making due to the unavailability
of a matched therapy. This amounts to almost three-
quarters (74%, n = 171) of the cohort being found to
harbour at least one actionable alteration, albeit with
variable clinical importance. Of ER+HER2− patients,
10% (n = 24) were found to carry ESR1 alterations, and
64% (n = 13) of patients with a BRCA1 or BRCA2 muta-
tion with a high variant allele fraction were recom-
mended for germline testing. Additionally, we found
several genes that were enriched in the metastatic setting
across the whole cohort, as well as discordant findings in
patients with both primary and metastatic samples,
highlighting the need to profile metastatic tissue where
possible. Finally, we found that higher mutation number
was also associated with worse survival. These findings
were obtained using a targeted panel sequencing far
fewer genes (around one-third) than some which are
commercially available. The outcomes of this study sug-
gest that a panel featuring only ESCAT LOE I/II genes,
equivalent to level 1 in this study, would be sufficient for
the majority of patients who could benefit from genomic
interrogation. These smaller and less expensive assays
may make genomic profiling more broadly accessible to
breast cancer patients and clinicians.
The distribution and frequency of metastatic genomic
alterations in this study are similar to the findings of
other studies, including enrichment of ESR1 mutations
believed to be the result of therapeutic selective pressure
[7, 10, 11, 34]. Mutations in ESR1 are almost exclusively
found in metastatic lesions of ER+HER2− patients, al-
though some studies have shown they can exist prior to
the onset of metastases in patients treated with endo-
crine therapies [35, 36]. This was observed in 2 patients,
shown in Fig. 3, where the primary samples were col-
lected post-endocrine therapy and had already developed
an ESR1 alteration. ESR1 mutations arise due to pro-
longed treatment with tamoxifen and aromatase inhibi-
tors; however, retrospective analysis of the PALOMA-2
and PALOMA-3 studies found that patients treated with
a selective oestrogen degrader either alone or in combin-
ation with CDK4/6 inhibitors also showed development
of ESR1 mutations [37–39].
Fig. 3 Concordance plot of primary and metastatic paired samples. Data for 76 patients and their paired sequenced samples is shown. Genetic
alterations included in this figure are putative driver genes observed in 2 or more samples. A further 4 patients and their paired samples have
been excluded from the figure because their pairs did not include the genes shown. Concordance scores for each gene is listed on the right of
the figure. Genes listed in red indicate that it is CN amplification concordance being compared, rather than mutation concordance (shown in
black text)
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Fig. 4 (See legend on next page.)
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As expected, TP53 alterations were the most prevalent
across all samples. Of all the level 1 actionable genes,
PIK3CA was found to be the most commonly altered,
consistent with other studies [34]. Recently, the α-
subunit specific PIK3CA inhibitor alpelisib was approved
for use in ER+HER2− MBC patients with hotspot
PIK3CA mutations, providing a matched therapy for this
most common alteration [34, 40, 41]. Conversely, the
finding that 25% of patients carried a level 2 alteration
which lack proven therapeutic options highlights the dif-
ficulties in matching the majority of patients with tar-
geted therapies. It is uncertain how many of these level
2 alterations may be clinically relevant in the near future.
Nevertheless, the high prevalence of PIK3CA alterations
alone means that a nearly a quarter of MBC patients
could be treated with a matched targeted therapy, even
accounting for those that could not have a metastatic
sample sequenced as there was a high concordance rate
(69% concordance) with the primary tumour.
Like other studies, we found a proportion of patients
(26%) did not carry a potentially actionable alteration.
Patients where no alteration was found may benefit from
more comprehensive genomic analysis such as whole-
genome sequencing, where mutational signatures such
as homologous recombination repair deficiency or more
rarely, microsatellite instability could be identified and
utilised for therapeutic decisions [42, 43].
Our concordance analysis in 81 patients with meta-
chronous primary and metastatic samples allows ob-
servation of how key driver genes change in
metastatic disease. Mutations in both TSC2 and
STK11 were found exclusively in metastatic samples
and are possibly associated with the development of
metastatic disease or resistance to therapy. The find-
ing that TSC2 was also enriched in our metastatic co-
hort compared to the TCGA primary data set also
supports this hypothesis [11]. The high frequency of
mutations in the genes RB1, TSC1 and FOXA1 in the
metastatic samples with few or no concordant cases
also suggests these genes are similarly relevant to the
biology of metastatic disease. Co-mutation analysis in
both the ER+HER2− and TNBC subgroups suggested
that RB1 may also play a key role in the emergence
of metastatic and treatment-resistant subclonal ele-
ments. This finding is supported by other studies that
have linked alterations in RB1 with resistance to
endocrine therapies and CDK4 inhibitors [10, 44, 45].
Our study has several limitations. Firstly, the somatic
landscape of the sequenced tumour may not be indica-
tive of the whole metastatic disease burden. Novel
methods such as circulating tumour DNA sequencing
could be utilised to avoid sampling bias and increase the
number of patients for whom genomic information is
available. Nevertheless there are still cases of discord-
ance between circulating tumour DNA and tumour
DNA from sequenced samples, and plasma sampling has
a higher rate of false negatives [1, 46]. Secondly, a panel
of the size employed in this study cannot accurately esti-
mate the true total mutation burden, and the mutation
number per sample reported here cannot be considered
a surrogate measure. Thirdly, the cohort of patients in
our study may not be representative of the general meta-
static breast cancer population as there was likely to be
some bias towards enrolling younger and fitter patients.
Fourthly, the rate at which patients receive therapies
matched to their genomic profile is subject to the avail-
ability of these therapies and clinical trials, which will
vary greatly across clinical contexts, and the timeframe
in which the genomic profile can be delivered. The latter
was heavily influenced by the time required to receive
tissue samples. Reducing this further will require closer
integration of pathology services with the treatment
team and greater awareness of the urgency of tissue re-
quests. Fifthly, consistent with other studies, we found
that a relatively high rate of patients could not be deliv-
ered a genomic profile due to the difficulty in obtaining
a suitable sample as 35% of samples had insufficient
DNA. Due to the inherent difficulties in obtaining meta-
static biopsies from MBC patients, these failure rates for
tumour sequencing are unlikely to improve.
Conclusion
This study has found that prospective genomic sequen-
cing for the management of MBC is both feasible and of
utility as an adjunct to standard management with 49%
of sequenced patients carrying a level 1 actionable alter-
ation. PIK3CA was the most common actionable muta-
tion, found in 52% (n = 71) of patients with a level 1
actionable alteration. Of patients referred for a clinical
trial with a matched therapy, 89% (n = 68) had a PIK3CA
mutation. We found that PIK3CA mutation status, and
genomic profiles in general, demonstrates within-patient
heterogeneity which is clinically relevant, although
PIK3CA was usually concordant across primary and
(See figure on previous page.)
Fig. 4 Prognostic associations in this cohort of sequenced metastatic breast cancer patients. a Overall survival by subtype for all recruited
patients (n = 323). b Overall survival of patients based on the mutational burden of 4 mutations (75th percentile) or more (n = 234). c Overall
survival of ER+HER2− patients based on the median mutation number of 4 or more (n = 163 patients). d Table of HR for all patients and all
subtypes by mutation number per sample. Patients were excluded if there was incomplete survival information. e Spread of TILs across distant
metastatic site (n = 123)
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metastatic samples. Nevertheless, the presence of gen-
omic heterogeneity indicates sequencing of metastatic le-
sions is preferred if possible. Due to the inherent
difficulties in obtaining biopsies of metastatic disease, the
combination of tumour and circulating tumour DNA se-
quencing is likely to be the optimal strategy to improve
the rate of successful genomic profiling. It is expected the
clinical utility of genomic profiling will increase over time
with greater availability of targeted therapies, as has
already transpired with the recent approval of the PIK3CA
inhibitor alpelisib. We conclude that where possible, pa-
tients with MBC should undergo molecular profiling.
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